Infinium Pharma
: INFINIUM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Infinium Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Infinium Pharmachem Ltd is a pharmaceutical company specialising in the development, manufacture, and export of iodine-based pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company operates as a GMP-compliant and FDA-approved entity, offering a diverse portfolio of over 250 intermediates and 15 APIs.
Business Model
The company generates revenue by manufacturing and supplying iodine derivatives on an 'order-to-made' basis for global clients. Its operations are supported by ISO 9001-2015 certification and adherence to stringent quality standards.
- Intermediates Portfolio:250+
- API Portfolio:15+
Growth Outlook
Growth is driven by the company's ability to provide customised iodine derivative solutions to the pharmaceutical sector. Continued focus on maintaining international quality certifications supports its export-oriented business model.
Key Risks
- Raw Material Price Volatility. Fluctuations in the global price of iodine can significantly impact the company's production costs and profit margins.
- Regulatory Compliance Risk. Failure to maintain GMP and FDA approvals could result in the loss of key export markets and operational disruptions.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect its competitive pricing and reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Infinium Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Infinium PharmaINFINIUM | ₹423 Cr | — | — | — | 11.0% | — | — | +7.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2026
Financials
Infinium Pharma
: INFINIUM · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Infinium Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Infinium Pharmachem Ltd is a pharmaceutical company specialising in the development, manufacture, and export of iodine-based pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company operates as a GMP-compliant and FDA-approved entity, offering a diverse portfolio of over 250 intermediates and 15 APIs.
Business Model
The company generates revenue by manufacturing and supplying iodine derivatives on an 'order-to-made' basis for global clients. Its operations are supported by ISO 9001-2015 certification and adherence to stringent quality standards.
- Intermediates Portfolio:250+
- API Portfolio:15+
Growth Outlook
Growth is driven by the company's ability to provide customised iodine derivative solutions to the pharmaceutical sector. Continued focus on maintaining international quality certifications supports its export-oriented business model.
Key Risks
- Raw Material Price Volatility. Fluctuations in the global price of iodine can significantly impact the company's production costs and profit margins.
- Regulatory Compliance Risk. Failure to maintain GMP and FDA approvals could result in the loss of key export markets and operational disruptions.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect its competitive pricing and reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Infinium Pharma and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026